

TILDRAKIZUMAB solution for injection (Ilumetri® ▼) for moderate to severe plaque psoriasis

The Pan Mersey Area Prescribing Committee recommends the prescribing of TILDRAKIZUMAB solution for injection (Ilumetri® ▼), by specialists only, for moderate to severe plaque psoriasis in accordance with NICE TA575

RED

Tildrakizumab is licensed for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy¹. Prescribing and monitoring of therapy must be retained by a specialist in the management of plaque psoriasis.

NICE technology appraisal [TA575](#)² recommends Tildrakizumab solution for injection (Ilumetri® ▼) as an option for treating moderate to severe plaque psoriasis only if:

- the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and
- the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and
- the company provides the drug according to the commercial arrangement

Consider stopping tildrakizumab between 12 weeks and 28 weeks if there has not been at least a 50% reduction in the PASI score from when treatment started.

Stop tildrakizumab at 28 weeks if the psoriasis has not responded adequately. An adequate response is defined as:

- a 75% reduction in the PASI score (PASI 75) from when treatment started or
- a 50% reduction in the PASI score (PASI 50) and a 5-point reduction in DLQI from when treatment started.

If patients and their clinicians consider tildrakizumab to be one of a range of suitable treatments, the least expensive should be chosen (taking into account administration costs, dosage, price per dose and commercial arrangements).

NICE do not expect this guidance to have a significant impact on resources; that is, it will be less than £5 million per year in England (or £9,100 per 100,000 population). This is because tildrakizumab is a further treatment option and is available at a similar price to existing options.

References

1. Almirall Limited. Summary of Product Characteristics: [Ilumetri 100 mg solution for injection in pre-filled syringe](#), 19 September 2018. Accessed online 28 March 2019.
2. National Institute for Health and Care Excellence. Tildrakizumab for treating moderate to severe plaque psoriasis. [NICE Technology Appraisal 575](#); 2019. Accessed 17 April 2019.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.